ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      83.205
      0.10%
      Bitcoin
      64,178.72
      0.28%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Canada
      5. TSX
      6. HLS Therapeutics Inc (HLS)

      7. HLS Therapeutics Inc (HLS) News

      HLS

      HLS Therapeutics (HLS)

      HLS Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:TSX:HLS
      DateTimeSourceHeadlineSymbolCompany
      04/25/20248:50AMPR Newswire (Canada)HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference CallTSX:HLSHLS Therapeutics Inc
      04/09/20246:30AMPR Newswire (Canada)HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceTSX:HLSHLS Therapeutics Inc
      04/08/20246:30AMPR Newswire (Canada)New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient SubgroupsTSX:HLSHLS Therapeutics Inc
      03/14/20246:30AMPR Newswire (Canada)HLS Therapeutics Announces Fiscal 2023 Financial ResultsTSX:HLSHLS Therapeutics Inc
      02/29/20246:30AMPR Newswire (Canada)HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference CallTSX:HLSHLS Therapeutics Inc
      02/06/20246:30AMPR Newswire (Canada)HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug PlanTSX:HLSHLS Therapeutics Inc
      12/18/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces CFO DepartureTSX:HLSHLS Therapeutics Inc
      11/14/20235:12PMPR Newswire (Canada)New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at BaselineTSX:HLSHLS Therapeutics Inc
      11/09/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer BidTSX:HLSHLS Therapeutics Inc
      10/26/20236:30AMPR Newswire (Canada)HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference CallTSX:HLSHLS Therapeutics Inc
      09/06/20238:30AMPR Newswire (Canada)HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment ConferenceTSX:HLSHLS Therapeutics Inc
      08/14/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces Updates to its Credit AgreementTSX:HLSHLS Therapeutics Inc
      08/10/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces Q2 Fiscal 2023 Financial ResultsTSX:HLSHLS Therapeutics Inc
      08/03/20236:29PMPR Newswire (Canada)HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference CallTSX:HLSHLS Therapeutics Inc
      06/22/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces Updates to its Board of DirectorsTSX:HLSHLS Therapeutics Inc
      06/16/20236:00PMPR Newswire (Canada)HLS Therapeutics Reports Annual Meeting ResultsTSX:HLSHLS Therapeutics Inc
      06/08/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of DirectorsTSX:HLSHLS Therapeutics Inc
      05/11/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces Q1 Fiscal 2023 Financial ResultsTSX:HLSHLS Therapeutics Inc
      05/03/20236:30AMPR Newswire (Canada)HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference CallTSX:HLSHLS Therapeutics Inc
      04/21/20236:30AMPR Newswire (Canada)HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceTSX:HLSHLS Therapeutics Inc
      04/17/20237:00AMPR Newswire (Canada)HLS Therapeutics Announces CEO TransitionTSX:HLSHLS Therapeutics Inc
      03/16/20236:30AMPR Newswire (Canada)HLS Therapeutics Announces Q4 and Fiscal 2022 Financial ResultsTSX:HLSHLS Therapeutics Inc
      03/02/20236:30AMPR Newswire (Canada)HLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference CallTSX:HLSHLS Therapeutics Inc
      11/29/20226:30AMPR Newswire (Canada)HLS Therapeutics Announces Board AppointmentTSX:HLSHLS Therapeutics Inc
      11/14/20226:30AMPR Newswire (Canada)HLS Therapeutics to Present at the Stifel Healthcare ConferenceTSX:HLSHLS Therapeutics Inc
      11/10/20226:30AMPR Newswire (Canada)HLS Therapeutics Announces Q3 Fiscal 2022 Financial Results and Renewal of Normal Course Issuer BidTSX:HLSHLS Therapeutics Inc
      11/07/202210:30AMPR Newswire (Canada)HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at the American Heart AssociationTSX:HLSHLS Therapeutics Inc
      10/27/20226:30AMPR Newswire (Canada)HLS Therapeutics to Host Q3 Fiscal 2022 Financial Results Conference CallTSX:HLSHLS Therapeutics Inc
      10/03/20226:30AMPR Newswire (Canada)HLS Therapeutics Announces Updates to its Credit AgreementTSX:HLSHLS Therapeutics Inc
      09/15/20226:30AMPR Newswire (Canada)HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on September 22, 2022TSX:HLSHLS Therapeutics Inc
       Showing the most relevant articles for your search:TSX:HLS